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ABSTRACT
Diffuse alveolar haemorrhage (DAH) is a catastrophic pulmonary complication of systemic lupus erythematosus. It can result in refractory 
hypoxaemia despite mechanical ventilation. Increasing lung compliance and worsening pulmonary hypertension can potentiate cardiogenic 
shock from acute right ventricular failure. In such patients with cardiopulmonary collapse, veno-arterial (V-A) ECMO maybe a viable option 
that can provide the required haemodynamic support. However, the use of V-A ECMO in such patients is limited due to an associated 
increased risk of bleeding. Our case report describes the successful use of V-A ECMO without the use of systemic anticoagulation in a 
patient with DAH. Despite the absence of systemic anticoagulation, no thrombotic complications within the circuit were noted. 
LEARNING POINTS
• Diffuse alveolar haemorrhage (DAH) complicating systemic lupus erythematous can present dramatically with sudden cardiopulmonary 
collapse. 
• Extracorporeal membrane oxygenation (ECMO) can provide temporary haemodynamic support until conventional medical therapy can 
take effect.
• Despite the historical increased bleeding risk associated with ECMO, it can be safely used in patients with DAH to provide time for 
underlying organ recovery.
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INTRODUCTION
Diffuse alveolar haemorrhage (DAH) is a rare but catastrophic complication of many systemic diseases. It classically presents with 
haemoptysis, dropping haemoglobin levels and new radiographic infiltrates. DAH can progress to hypoxaemic respiratory failure requiring 
mechanical ventilation, which is a poor prognostic marker[1]. DAH is seen in systemic lupus erythematosus (SLE), although more commonly 
in patients with underlying lupus nephritis[1]. Despite optimal medical therapy, outcomes remain highly variable. Extracorporeal membrane 
oxygenation (ECMO) has been used as a bridge or temporary support in potentially severe, reversible pulmonary and/or cardiac dysfunction 
refractory to conventional medical therapy. However, the use of systemic anticoagulation while on ECMO may be associated with increased 
risk of bleeding[2] that could limit its utility in patients with DAH. In this clinical vignette, we describe the successful use of veno-arterial 
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extracorporeal membrane oxygenation (V-A ECMO) without anticoagulation in a patient with refractory hypoxaemia and cardiopulmonary 
collapse resulting from SLE-induced DAH. 
CASE REPORT
A 38-year-old woman presented with fever, cough, haemoptysis and chest pain for 1 day. She had been diagnosed with SLE-induced type 
IV lupus nephritis (mixed membranous and diffuse proliferative lupus glomerulonephritis with 45% crescents) and was being treated with 
prednisolone and mycophenolate.
On physical examination, her respiratory rate was 25 breaths per minute, pulse 100 beats per minute, blood pressure 122/79 mmHg and 
temperature 38.5°C with crackles over the lower lung fields. Initial laboratory test results revealed a haemoglobin of 6.6 g/dl and the chest 
x-ray (Fig. 1A) was consistent with bilateral alveolar infiltrates. An arterial blood gas (ABG) revealed a pH of 7.37, a Paco
2
 of 26, a Pao
2
 of 95 
and an HCO
3 
of 15 on an Fio
2
 of 0.35 on a Venturi mask. The patient was diagnosed with DAH and immediately started on high-dose methyl 
prednisolone and mycophenolate (at her home dose). 
Over the next 2 hours, she continued to have haemoptysis and worsening hypoxaemia with increasing bilateral infiltrates on CT scan (Fig. 
1B). She was intubated and transferred to the intensive care unit (ICU) where she had a pulseless electrical arrest but was revived with chest 
compressions. A bedside echocardiogram demonstrated a hypokinetic and dilated right ventricle with markedly elevated pulmonary artery 
pressure for which she was started on dobutamine.
Despite maximal ventilatory management, sedation, neuro-muscular blockade and maximal vasopressor support, the patient did not 
improve. She had worsening respiratory acidosis on ABG (pH of 6.96, a Paco
2
 of 61, a Pao
2 
of 59 and an HCO
3
 of 14 on an Fio
2
 of 1.0) and 
hence V-A ECMO was initiated
A chest x-ray (Fig. 1C) obtained the following day showed worsening airspace disease. However, the patient was continued on V-A ECMO. 
The ventilator was maintained at an Fio
2
 of 0.5, positive end-expiratory pressure (PEEP) of 8, tidal volume of 185 ml and respiratory rate of 
8 breaths per minute. Intravenous methyl prednisolone and plasmapheresis were continued.
On day 3 of V-A ECMO, the patient demonstrated improved cardiac output, decreased vasopressor requirement and increased lung 
compliance. Her chest x-ray (Fig. 1D) and ABG also showed significant improvement (pH of 7.48, a Paco
2
 of 36, a Pao
2
 of 267 and an HCO
3
 of 27 
on an FIO
2 
of 0.5 and PEEP of 8). V-A ECMO was discontinued on day 3. The patient was successfully extubated on day 5 and plasmapheresis 
was stopped on day 6. Over the next 3 weeks she improved steadily and was finally discharged home. 
Figure 1. Patient’s imaging (A) at admission, 
(B) 2 hours after admission, (C) 11 hours after 
the initiation of veno-arterial extracorporeal 
membrane oxygenation (V-A ECMO), and (D) on 
the third day of V-A ECMO.
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DISCUSSION
Diffuse alveolar haemorrhage (DAH) is characterized by the extravasation of red blood cells into the pulmonary alveolar spaces from a 
disruption of the alveolar capillary interface. Histologically, DAH can arise from small vessel vasculitis (capillaritis), diffuse alveolar damage 
or bland haemorrhage from underlying coagulopathy and/or pulmonary venous hypertension[3]. All these histological sub-types can be 
associated with SLE-induced DAH[1, 3], although pulmonary capillaritis is the most common. The treatment for SLE-induced DAH includes 
high-dose corticosteroids often in combination with cyclophosphamide, mycophenolate or rituximab. Despite the lack of controlled clinical 
trials, plasmapheresis is often used in the acute setting. 
Our patient had SLE-induced DAH that resulted in fulminant hypoxaemic respiratory failure, coupled with refractory obstructive shock. 
Since its first successful use in 1972, veno-venous (V-V) ECMO has gained popularity as a salvage therapy in severe but potentially reversible 
hypoxaemic respiratory failure. However, V-A ECMO maybe a necessary alternative in the setting of acute right heart failure from severe 
acute lung injury. Traditionally, the use of systemic anticoagulation while on ECMO has limited its use in patients with increased risk of 
bleeding[2]. However, recent technical advances in the extracorporeal circuit have allowed for the reduction[4] or omission of systemic 
anticoagulation in this sub-group of patients[5]. Here we describe the successful use of V-A ECMO in our patient who had massive haemoptysis 
with hypoxaemic respiratory failure from DAH coupled with severe acute right heart failure from severely elevated pulmonary pressures. In 
this advanced but potentially reversible setting, ECMO provided our patient with temporary haemodynamic support. As evidenced by our 
patient’s remarkable recovery during this period, it can be speculated that V-A ECMO may have provided our patient with the additional 
time required for the recovery of the with the help of appropriate medical management. 
Our case report contributes to the scant literature supporting the use of V-A ECMO as a viable option in patients with refractory hypoxaemia 
and reversible haemodynamic collapse from acute right heart failure due to acute lung injury.
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